315703-52-7

中文名称 N-(4-乙氧基苯基)-4-(2-甲基咪唑并[1,2-A]吡啶-3-基)噻唑-2-胺

英文名称 N-(4-Ethoxyphenyl)-4-(2-methylimidazo[1,2-a]pyridin-3-yl)thiazol-2-amine

CAS 315703-52-7

分子式 C19H18N4OS

分子量 350.44

MOL 文件 315703-52-7.mol

更新日期 2023/03/20 15:41:25

315703-52-7 结构式

基本信息物理化学性质安全数据 N-(4-乙氧基苯基)-4-(2-甲基咪唑并[1,2-A]吡啶-3-基)噻唑-2-胺价格(试剂级) 常见问题列表

基本信息

中文别名

化合物JK184
HEDGEHOG(HH)抑制剂(JK184)
N-(4-乙氧基苯基)-4-(2-甲基咪唑并[1,2-A]吡啶-3-基)噻唑-2-胺
N-(4-乙氧苯基)-4-(2-甲基咪唑并-[1,2-A]吡啶-3-基)噻唑-2-胺

英文别名

JK 184
CS-2369
JK184 (JK-184
Hh Signaling Antagonist VII
Hh Signaling Antagonist VII, JK184
JK 184
JK-184
HH SIGNALING ANTAGONIST VII
Hh Signaling Antagonist VII, JK184 - CAS 315703-52-7 - Calbiochem
N-(4-Ethoxyphenyl)-4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-thiazolamine
N-(4-Ethoxyphenyl)-4-(2-methylimidazo[1,2-a]pyridin-3-yl)thiazol-2-amine
2-ThiazolaMine, N-(4-ethoxyphenyl)-4-(2-MethyliMidazo[1,2-a]pyridin-3-yl)-

所属类别

生物化工：生化试剂

物理化学性质

储存条件Keep in dark place,Inert atmosphere,2-8°C

溶解度二甲基亚砜：≥20mg/mL

形态粉末

颜色灰白色至浅棕色

安全数据

危险性符号(GHS)

GHS05,GHS07

警示词危险

危险性描述H302-H318

防范说明P280-P305+P351+P338

危险品标志Xn

危险类别码22-41

安全说明26-36

WGK Germany3

N-(4-乙氧基苯基)-4-(2-甲基咪唑并[1,2-A]吡啶-3-基)噻唑-2-胺价格(试剂级)

报价日期	产品编号	产品名称	CAS号	包装	价格
2024/04/30	HY-13307	N-(4-乙氧基苯基)-4-(2-甲基咪唑并[1,2-A]吡啶-3-基)噻唑-2-胺 JK184	315703-52-7	5 mg	450元
2024/04/30	HY-13307	N-(4-乙氧基苯基)-4-(2-甲基咪唑并[1,2-A]吡啶-3-基)噻唑-2-胺 JK184	315703-52-7	10mM * 1mLin DMSO	495元
2024/04/30	HY-13307	N-(4-乙氧基苯基)-4-(2-甲基咪唑并[1,2-A]吡啶-3-基)噻唑-2-胺 JK184	315703-52-7	10mg	750元

常见问题列表

生物活性

JK184抑制Hedgehog信号通路中的Gli，在哺乳动物细胞中IC50为30 nM。

靶点

Target	Value
Gli ()

体外研究

JK184 is designed to antagonize Hh signaling by inhibiting glioma (Gli)-dependent transcriptional activity in a dose dependent manner. JK184 significantly inhibitts proliferation of HUVECs with IC ₅₀ of 6.3 μg/mL after three days incubation. To evaluate anti-tumor effect of JK184, MTT assay is conducted in Panc-1 and BxPC-3 cells after administration with indicated concentrations of compounds, half maximal inhibitory concentration (IC ₅₀ ) of JK184 (23.7 ng/mL in anc-1 and 34.3 ng/mL in BxPC-3). Claudin-low cell lines are more sensitive to JK184 treatment than are MCF10a, MTSV1-7, or HMLE-shGFP and HMLE-pBP cells, and JK184 induced a dose-dependent decrease in glioma-associated oncogene homolog 1 ( GLI1 ) transcript and protein levels in these cells. Treatment with the IC ₅₀ dose of JK184 enhances the proportion of HMLE-shEcad cells that stained with Annexin-V, but are negative for propidium iodide (PI) (P<0.0001, t test).

体内研究

JK184 (5 mg/kg, injected intravenously) exhibits good anti-proliferative activity in subcutaneous Panc-1 and BxPC-3 tumor models, and is a good candidate as antitumor drug targeted Hh signaling. However, JK184 has a poor pharmacokinetic profile and bioavailability.